흑색종에서 칼슘 채널 차단제에 의한 엑소좀 분비 억제를 통한 면역 관문 억제 효능 규명

• 영문명: Characterization of Immune Checkpoint Inhibition Efficacy through Inhibition of Exosome Secretion by Calcium Channel Blockers in Melanoma
• 발행기관: 대한약학회
• 저자명: 라키불알람(Rakibul Alam) 김종인(Jong-In Kim) 이찬형(Chan-Hyeong Lee) 박성식(Seong-Sik Park) 백문창(Moon-Chang Baek)
• 간행물 정보: 『약학회지』제65권 제4호(2021년), 313~320쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2021.08.31

영문 초록

Melanoma is a belligerent cutaneous malignancy. Multiple therapeutic options, including immunotherapy and targeted therapy, have shown remarkable promise in treating metastatic melanoma. Exosomes containing programmed cell death ligand 1 (PD-L1) secreted from melanoma bind to programmed cell death 1 (PD-1) on the surface of CD8+ T cells. As a result, melanoma not only evades the immune surveillance of CD8+ T cells but also inhibits their activation and facilitates the growth and proliferation of cancer cells. In this study, we identified nicardipine, an FDA-approved L-type calcium channel inhibitor, which downregulates the expression of proteins involved in exosome biogenesis and secretion as well as exosomal PD-L1 secretion, from metastatic melanoma cells. Furthermore, nicardipine suppresses PD-L1 expression after interferon-γ-mediated stimulation and enhances CD8+ cell function, similar to the function of PD-L1- blocking antibodies in cancer therapies. This could lead to the development of next-generation anticancer drugs for the treatment of metastatic melanoma.

목차

서 론(Introduction)

방 법(Methods)

결과 및 고찰(Results and Discussion)

결 론(Conclusion)

감사의 말씀(Acknowledgment)

Conflict of Interest

References

키워드

Melanoma Exosomes PD-L1 Immunosuppression Calcium channel blocker